https://www.selleckchem.com/pr....oducts/danirixin.htm
OBJECTIVE Impulsive decision-making is characterized by actions taken without considering consequences. Patients with Parkinson's disease (PD) who receive dopaminergic treatment, especially dopamine agonists, are at risk of developing impulsive-compulsive behaviors (ICBs). We assessed impulse-related changes across a large heterogeneous PD population using the Barratt impulsivity scale (BIS-11) by evaluating BIS-11 first- and second-order factors. METHODS We assessed a total of 204 subjects 93 healthy controls (HCs), and 68 ICB- and 4